Therefore, based on the structural combination of nicotinic ligands and antidepressants, it seems attractive to search for and design compounds that act as multi-target therapeutic ligands in α4β2 nAChRs, DAT and/or SERT for the treatment of anxiety and depressive disorders [43,44]. This evidence concerns the gene SLC6A4 and Anxiety.